{'fraction_non_alphanumeric': 0.025201612903225805, 'fraction_numerical': 0.015120967741935484, 'mean_word_length': 5.576158940397351, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Topical treatment of glucocorticoid-sensitive dermatoses with diflorasone diacetate].

Treatment with diflorasone diacetate ointment and cream (0.05%) was strikingly successful in a multicenter clinical trial involving 4,651 patients in total suffering from various corticosteroid-sensitive dermatoses. According to the clinical evaluation, 93% of the patients were cured or much improved. Approximately 7% of the patients questioned rated the local tolerance of the two forms of administration as good to very good. Only 4% of the patients rated the tolerance of the ointment or cream as moderate or bad. None of the patients showed any systemic side-effects. The molecular structure of diflorasone-17,21-diacetate and the specific pharmaceutical properties of the ointment and cream evidently guarantee a good bioavailability of the glucocorticosteroid in the skin. Clinical and experimental results confirm that diflorasone diacetate belongs to the group of highly active corticosteroids.